Wall Street analysts forecast HLF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HLF is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast HLF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HLF is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 14.900
Low
10.00
Averages
10.00
High
10.00
Current: 14.900
Low
10.00
Averages
10.00
High
10.00
Citi
Buy
maintain
$11 -> $17
2025-12-12
New
Reason
Citi
Price Target
$11 -> $17
2025-12-12
New
maintain
Buy
Reason
Citi raised the firm's price target on Herbalife to $17 from $11 and keeps a Buy rating on the shares after meeting with management. The firm believes Herbalife is building a "flywheel" amid strong distributor enthusiasm. Citi now has increased confidence that the company can hit its target for sales growth in 2026.
Mizuho
John Baumgartner
Neutral
maintain
$10 -> $11
2025-11-26
Reason
Mizuho
John Baumgartner
Price Target
$10 -> $11
2025-11-26
maintain
Neutral
Reason
Mizuho analyst John Baumgartner raised the firm's price target on Herbalife to $11 from $10 and keeps a Neutral rating on the shares. The firm believes the company's fundamentals remain on a "recovery path." Herbalife's evolution under new CEO Stephan Gratziani is "increasingly encouraging," the analyst tells investors in a research note. Mizuho says a return to corporate volume growth is possible in fiscal 2026. It upped estimates for Herbalife.
Argus
John Staszak
Hold
to
Buy
upgrade
2025-11-26
Reason
Argus
John Staszak
Price Target
2025-11-26
upgrade
Hold
to
Buy
Reason
Argus analyst John Staszak upgraded Herbalife to Buy from Hold.
Argus
Hold
to
Buy
upgrade
2025-11-26
Reason
Argus
Price Target
2025-11-26
upgrade
Hold
to
Buy
Reason
As previously reported, Argus upgraded Herbalife to Buy from Hold. The firm cites the company's Q3 earnings beat reported earlier this month while also boosting its FY25 EPS view by 3c to $2.15 and its FY26 view by 4c to $2.64, the analyst tells investors in a research note. Argus adds however that while Herbalife's reported revenue rose 270bps y/y, it was hurt by foreign currency headwinds.
About HLF
Herbalife Ltd. is a global nutrition company. The Company sells weight management; targeted nutrition; energy, sports and fitness; and other nutrition products to and through a network of independent members. The Company has two geographical segments: Primary Reporting Segment (North America, Latin America, EMEA (Europe, Middle East, and Africa), and Asia Pacific regions) and China. Its products are classified into five categories. The Weight Management category includes meal replacements, protein shakes, drink mixes, weight loss supplements, healthy snacks, and metabolism-boosting teas. The Targeted Nutrition category features functional beverages and dietary supplements. The Energy, Sports, and Fitness category consists of products that support a healthy and active lifestyle. The Outer Nutrition segment offers facial skincare, body care, and hair care products. The Literature and Promotional Items include start-up kits, sales tools, and educational materials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
